Dr. Robert I. Haddad, MD

Medicare patients and services

Medicare patients, 2024

153

Services billed

383

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 13 companies reported 81 payments worth $111,352 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $967,878 in research payments for these studies, mostly to the institutions running them.

• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
  Aveo Pharmaceuticals, Inc. · Recruiting · NCT06064877
• Head And Neck Cancer Squamous Cell Carcinoma
  Aveo Pharmaceuticals, Inc.
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great t…
  Incyte Corporation
• A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not …
  AstraZeneca Pharmaceuticals LP
• Phase II, multi cohort trial of neoadjuvant and post surgery IO102 IO103 and pembrolizumab in patients with selected resectable tumors
  Merck Sharp & Dohme LLC
• A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head …
  Exelixis Inc.
• Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer
  Genentech, Inc.
• A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L interve…
  Merck Sharp & Dohme LLC
• A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Nec…
  Merck Sharp & Dohme LLC
• A phase 2, randomized, open-label, platform study using a master proto
  GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Boston

• Janet L. Abrahm, MD
• Thomas A. Abrams, M.D.
• Jeremy S. Abramson, MD
• Nana O. Addo-tabiri, MD
• Adeboye H. Adewoye, M.D.
• Neeraj Agarwal, MD
• Andrew J. Aguirre, MD, PHD
• Inhye Ahn, M.D.